Relevant conflicts of interest/financial disclosures: Nothing to report.
Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome
Article first published online: 21 OCT 2013
Copyright © 2013 Movement Disorder Society
Volume 29, Issue 1, pages 126–130, January 2014
How to Cite
Wijemanne, S., Wu, L. J.C. and Jankovic, J. (2014), Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov. Disord., 29: 126–130. doi: 10.1002/mds.25692
Full financial disclosures and author roles may be found in the online version of this article.
Drs. Wijemanne and Wu have nothing to disclose.
Below is Dr. Jankovic's full disclosure: During the past two years Dr. Jankovic has received: Research and Center of Excellence Grants: Allergan, Inc; Ceregene, Inc; CHDI Foundation; GE Healthcare; Huntington's Disease Society of America; Huntington Study Group; Ipsen Limited; Lundbeck Inc; Michael J Fox Foundation for Parkinson Research; Medtronic; Merz Pharmaceuticals; National Institutes of Health; National Parkinson Foundation; St. Jude Medical; Teva Pharmaceutical Industries Ltd; UCB Inc; University of Rochester; Parkinson Study Group. Compensation/honoraria for services as a consultant or an advisory committee member: Allergan, Inc; Auspex Pharmaceuticals, Inc; Ipsen Biopharmaceuticals, Inc.; Lundbeck Inc; Merz Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Biosciences; US World Meds. Royalties: Cambridge; Elsevier; Future Science Group; Hodder Arnold; Lippincott Williams and Wilkins; Wiley-Blackwell. During the past two years Dr. Jankovic has served on the following editorial boards and foundation advisory boards without financial compensation: Editorial boards: Medlink: Neurology; Expert Review of Neurotherapeutics; Neurology in Clinical Practice; The Botulinum Journal; PeerJ; Therapeutic Advances in Neurological Disorders; Neurotherapeutics; Tremor and Other Hyperkinetic Movements; Journal of Parkinson's Disease; UpToDate. Foundations and non-Profit Organizations: American Academy of Neurology; Benign Essential Blepharospasm Research Foundation; Dystonia Medical Research Foundation; International Essential Tremor Foundation; International Neurotoxin Association; Michael J Fox Foundation for Parkinson Research. Speakers Bureau: none. Stock Ownership: none.
- Issue published online: 23 JAN 2014
- Article first published online: 21 OCT 2013
- Manuscript Accepted: 1 SEP 2013
- Manuscript Revised: 21 AUG 2013
- Manuscript Received: 17 APR 2013
This article has been cited by:
- 1Advances in Tourette Syndrome, Pediatric Clinics of North America, 2015, 62, 3, 687, ,
- 2Largest Study to Date Finds Psychiatric Comorbidities Are Very Common in Tourette Syndrome, Neurology Today, 2015, 15, 8, 12,
- 4Tics and Tourette Syndrome, Neurologic Clinics, 2015, 33, 1, 115, ,
- 5Neurobehavioral aspects, pathophysiology, and management of Tourette syndrome, Current Opinion in Neurology, 2014, 27, 4, 484, , ,
- 6The Role of Atypical Antipsychotics for Treatment of Tourette’s Syndrome: An Overview, Drugs, 2014, 74, 11, 1177,